Navigation Links
Niutang Sucralose Patent Litigation Successfully Concluded
Date:6/1/2009

Tate & Lyle will not appeal ITC decision; Voluntarily dismisses District Court case

BREA, Calif., June 1 /PRNewswire/ -- Changzhou Niutang, one of the largest global manufacturers of sucralose, and its U.S. subsidiary, US Niutang, today announced that Tate & Lyle will not appeal the recent decision made by the U.S. International Trade Commission that decisively rejected Tate & Lyle's infringement allegations against Niutang. In addition, Tate & Lyle has requested a voluntary dismissal of the patent infringement allegations it brought against Niutang in the United States District Court.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090528/CG23830LOGO)

"We are delighted to have all aspects of this litigation successfully concluded, with a complete victory in favor of Niutang," said Licheng Wang Jr., General Manager of Changzhou Niutang. "We will continue to focus our attention on what we do best - providing the highest quality sweeteners and food additives along with outstanding service to our worldwide customers."

Niutang has steadily grown its sucralose customer base, which now spans North America, Central America, South America, Europe and Asia. Niutang is already one of the largest manufacturers of aspartame in the world, and it has built upon that successful track record in growing its sucralose business.

"Niutang's sucralose sales have more than tripled from 2007 to 2008," continued Wang. "We recently completed the expansion of our sucralose capacity to 300 metric tons and have announced our plans to increase our capacity to 500 metric tons by 2012. As our sucralose business continues to grow, we remain committed to providing our customers with the high-quality products and unsurpassed level of customer service they have come to expect from Niutang."

Niutang is one of the largest and most experienced global manufacturers of sucralose. The company's established track record is built upon the highest standards of quality control, with products that are:

  • Manufactured according to cGMP requirements as stated in CFR 21 Part 110
  • Produced to meet all quality specifications required by current FCC
  • Moody International ISO 9001:2000/cGMP/HACCP certified
  • Kosher and Halal certified
  • Registered with the U.S. FDA in accordance with the Security and Bioterrorism Preparedness and Response Act of 2002

About Niutang

Niutang Chemical is one of the world's leading manufacturers and distributors of food additives, chemicals and pharmaceutical intermediates that are instrumental to food, beverage, pharmaceutical, nutraceutical and industrial products. Established in 1969, Niutang's commitment to producing the highest quality food additives at competitive prices has ensured its rapid growth into a leading global manufacturer of aspartame, folic acid, and more recently, sucralose. The company is certified in meeting the most stringent U.S. and European manufacturing, compliance and quality benchmarks. Based in China, Niutang also has sales and quality control operations in the United States and Europe that support its strong reputation for integrity and customer service. The company's website is www.niutang.com. For inquiries regarding Niutang Sucralose sales, please contact sales@niutang.us.

    For more information:

    Doreen Lubeck
    DJ Lubeck, LLC
    773-583-4331
    djlubeck@yahoo.com


'/>"/>
SOURCE Niutang Chemical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Niutang to Expand Sucralose Capacity 66 Percent by 2012
2. Niutang Recruits Seasoned Executive to Open U.K. Office
3. GDFII/L&P Sucralose Win Over Competitor Tate & Lyle
4. SENOMYX RECEIVES GENERALLY RECOGNIZED AS SAFE (GRAS) DETERMINATION FOR S2383 SUCRALOSE ENHANCER
5. Falcon Genomics Awarded Patent for Innovative Cancer Test
6. Viral Genetics Has Option Under Issued Key Patent for Cancer Drug
7. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
8. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
9. Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force
10. Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
11. Palomar Wins Two European Hair Removal Patent Opposition Hearings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 03, 2016 , ... ... its FDA approved sSOIP telemedicine stethoscope software that enables the stethoscope stream to ... called PCP-SSP and works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research ... issue representing international (non-US) based authors, the third volume of PXJ continues to ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Civilian Corps of the U.S. ... civilian nurses that care for its uniformed service members, the retired service members, their ... designating May 6th through May 12th National Nurses Week. It acknowledges the hard work ...
(Date:5/2/2016)... ... 2016 , ... In honor of National Physical Fitness and Sports Month in ... their fitness journey on social media. , The foot care company, which specializes ... product voucher each week during May to one winner. , “Whether the goal is ...
(Date:5/2/2016)... ... , ... Over $60 Billion is spent annually on products for our favorite ... review site for Toys, Tots, Pets & More (TTPM) announced the 15 winners of ... the Metropolitan Pavilion in New York City. , Chosen from a field of hundreds ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... heute bekannt, dass sie einen entscheidenden Meilenstein ... haben: Ein Aufruf zum Handeln, um Patientenresultate ... Veröffentlichung trägt zu Fortschritten im Verständnis der ... hervor, ein Bewusstsein für Hepatische Enzephalopathie in ...
(Date:5/2/2016)... N.J. , May 2, 2016  Celsion ... development company, today announced data from the first ... escalating clinical trial (the OVATION Study) combining GEN-1, ... care for the treatment of newly-diagnosed patients with ... followed by interval debulking surgery.  In the first ...
(Date:4/29/2016)... 2016 Interview ... Sanofi, leader mondial et diversifié ... pour le premier trimestre 2016. Le ... commente les résultats du premier trimestre ... le reste de l,année. ...
Breaking Medicine Technology: